Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07686263 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Interventions: Placebo (Drug), Xanomeline/Trospium Chloride (Drug) to Placebo (Drug), Xanomeline/Trospium Chloride (Drug) Eligibility criteria expanded, about 17 words · Study sites revised (59) Show 2 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Study sites revised (59)
  2. Recruitment opened Study sites: 61 to 59 · Start date changed from estimate of Sep 3, 2026 to Aug 20, 2026v2 Show 2 more changesShow less
    • Study sites: 61 to 59
    • Start date changed from estimate of Sep 3, 2026 to Aug 20, 2026
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
Trial Details
NCT Number NCT07686263
Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Conditions Schizophrenia
Enrollment 472 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov